http://www.takeda.com/ IR News http://www.takeda.com/ http://www.takeda.com/favicon.ico icon http://www.takeda.com/investor-information/quarterly-results/article_18140.html Presenters: Director, Chief Medical & Scientific Officer, Tadataka Yamada, M.D. [¥n] Senior Vice President, Finance & Accounting Department, Hiroshi Takahara 2012-02-01T15:00:00+09:00 http://www.takeda.com/press/article_44988.html Osaka, Japan, Cambridge, Mass and Tokyo, Japan, January 27, 2012 – Takeda Pharmaceutical Company Limited (“Takeda”) and Millennium: The Takeda Oncology Company (“Millennium”) today announced that Takeda Bio Development Center Limited (“Takeda Bio”) has initiated enrollment of patients in Japan for the two ongoing global Phase III clinical trials for the anti-prostate cancer investigational agent, orteronel(TAK-700). 2012-01-27T15:00:00+09:00 http://www.takeda.com/press/article_44980.html CAMBRIDGE, Mass., January 23, 2012–Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE® (bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy. 2012-01-24T09:00:00+09:00 http://www.takeda.com/press/article_44972.html OSAKA, Japan, January 18, 2012 – Takeda Pharmaceutical Company Limited (“Takeda”, TSE: 4502) announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture, as outlined in its 2011-2013 Mid-Range Plan (MRP). 2012-01-18T18:00:00+09:00 http://www.takeda.com/press/article_44965.html Osaka, Japan, January 18 2012 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced today that its New Drug Application (NDA) for its investigational compound AZILVA (generic name: azilsartan) for the treatment of hypertension has been approved by the Ministry of Health, Labour and Welfare. Discovered by Takeda, azilsartan is an angiotensin II receptor blocker (“ARB”) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. Azilva is a once-daily, orally administered single tablet, and the approved doses are 20 mg and 40 mg. 2012-01-18T15:00:00+09:00